Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

被引：0
|
作者：
Avasarala, Jagannadha [1 ]
机构：
[1] Univ Kentucky Med Ctr, Dept Neurol, 740 S Limestone, Lexington, KY 40536 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷 / 12期
关键词：
Anti-CD20; drugs; B cell repopulation; CD19 cell counts; COVID; 19; susceptibility; dosing frequency; multiple sclerosis; vaccine response; DEPLETION;
D O I：
10.1111/bcp.16248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：3094 / 3096
页数：3
相关论文
共 50 条
  • [31] Comparison of anti-CD20 therapies versus other disease modifying therapies on postpartum disease activity in patients with multiple sclerosis
    Passeri, M.
    Alvarez, E.
    Shah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 462 - 462
  • [32] Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
    Nishikubo, Masashi
    Shimomura, Yoshimitsu
    Yamamoto, Ryusuke
    Yoshioka, Satoshi
    Maruoka, Hayato
    Nasu, Seiko
    Nishioka, Tomomi
    Sakizono, Kenji
    Mitsuyuki, Satoshi
    Kubo, Tomoyo
    Okada, Naoki
    Nakagawa, Daishi
    Kamijo, Kimimori
    Imoto, Hiroharu
    Nagai, Yuya
    Hiramoto, Nobuhiro
    Yonetani, Noboru
    Kondo, Tadakazu
    Miyakoshi, Chisato
    Doi, Asako
    Ishikawa, Takayuki
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [33] Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
    Masashi Nishikubo
    Yoshimitsu Shimomura
    Ryusuke Yamamoto
    Satoshi Yoshioka
    Hayato Maruoka
    Seiko Nasu
    Tomomi Nishioka
    Kenji Sakizono
    Satoshi Mitsuyuki
    Tomoyo Kubo
    Naoki Okada
    Daishi Nakagawa
    Kimimori Kamijo
    Hiroharu Imoto
    Yuya Nagai
    Nobuhiro Hiramoto
    Noboru Yonetani
    Tadakazu Kondo
    Chisato Miyakoshi
    Asako Doi
    Takayuki Ishikawa
    Blood Cancer Journal, 13
  • [34] Sequential cellular and humoral responses after repetitive COVID-19 vaccination in patients treated with anti-CD20 antibodies
    Nishikubo, Masashi
    Shimomura, Yoshimitsu
    Yamamoto, Ryusuke
    Maruoka, Hayato
    Nasu, Seiko
    Sakizono, Kenji
    Nagai, Yuya
    Hiramoto, Nobuhiro
    Yonetani, Noboru
    Kondo, Tadakazu
    Miyakoshi, Chisato
    Doi, Asako
    Ishikawa, Takayuki
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 821 - 825
  • [35] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes"
    Rolfes, Leoni
    Meuth, Sven G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 691 - 693
  • [36] Preexisting humoral immunity for measles and varicella zoster in patients with multiple sclerosis after exposure to anti-CD20 therapies: does protection wane?
    Carvajal, Rene
    Tur, Carmen
    Carbonell, Pere
    Cobo Calvo, Alvaro
    Arino, Helena
    Aroca Alisina, Montse
    Arrambide, Georgina
    Bollo, Luca
    Bravo, Gabriel
    Cardenas-Robledo, Simon
    Castillo-Justribo, Joaquin
    Comabella, Manuel
    Esperalba, Juliana
    Galan, Ingrid
    Sarreon, Alexis
    Guio-Sanchez, Claudia
    La Puma, Delon
    Midaglia, Luciana
    Pappolla, Agustin
    Robles Sanchez, Miguel Angel
    Rodriguez-Barranco, Marta
    Rodriguez, Breogan
    Rio, Jordi
    Tagliani, Paula
    Vidal-Jordana, Angela
    Vilaseca, Andreu
    Zabalza, Ana
    Sastre-Garriga, Jaume
    Montalban, Xavier
    Tintore, Mar
    Otero-Romero, Susana
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 29 - 31
  • [37] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary
    Gratch, Daniel
    Zhovtis Ryerson, Lana
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 695 - 696
  • [38] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [39] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [40] Anti-CD20 therapies are associated with decreased seropositivity in patients with multiple sclerosis and related diseases: one-year pandemic experience of the New York COVID-19 Neuroimmunology Consortium (NYCNIC)
    Klineova, S.
    Harel, A.
    Farber, R. Straus
    DeAngelis, T.
    Zhang, Y.
    Hentz, R.
    Leung, T. M.
    Fong, K.
    Smith, T.
    Blanck, R.
    Zhovtis-Ryerson, L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 553 - 554
12345